The Global Escitalopram tablet market presents a comprehensive analysis of the Escitalopram tablet market by end-user/application (Treatment, Depression, Anxiety Disorder, Others and Research Studies), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up.
Market Snapshot:
Escitalopram tablet is the film-coated, round tablets containing escitalopram oxalate for treating depression, anxiety, panic and obsessive-compulsive disorders. It is a selective serotonin re-uptake inhibitor (SSRI) anti-depressant, which can ease the symptoms of the depression stages from moderate to severe. These drugs shows precise and better selectivity for serotonin reuptake transporter when compared to citalopram. It functions through acting directly on the serotonin-system through escalating level of serotonin. Commercially, it is available in different dosage ranging from 5mg, 10mg and 20mg.
Market Drivers
- Availability of generic tablets
- Rise in the population suffering from anxiety
Restraints
- Serious side effects associated with the Escitalopram tablet
Geographic Segmentation and Analysis
This section of our report presents a realistic picture of the Global Escitalopram tablet industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)